Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour

被引：8

作者：

Acres, Bruce ^{[2
]}

Lacoste, Gisele ^{[1
]}

Limacher, Jean-Marc ^{[1
]}

机构：

[1] Transgene SA, Dept Med Affairs, 400 Blvd Gonthier Andernach,Parc Innovat CS80166, F-67405 Illkirch Graffenstaden, France

[2] Bruce Acres Consulting, Strasbourg, France

来源：

CANCER VACCINES | 2017年 / 405卷

关键词：

CELL LUNG-CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; BLP25 LIPOSOME VACCINE; PHASE-I TRIAL; MUC1; IMMUNOTHERAPY; PANCREATIC-CANCER; IMMUNE-RESPONSES; DENDRITIC CELLS; BLADDER-CANCER; CORE-PROTEIN;

D O I：

10.1007/82_2015_429

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several approaches to antigen-specific immunotherapy of cancer antigen-specific immunotherapy of cancer have been tested clinically. In this chapter, we will describe studies done with the antigen MUC1. Tested MUC1 therapeutic vaccines include the following: monoclonal antibodies (MAbs) specific for MUC1; synthetic and recombinant polypeptides from the protein sequence of MUC1; dendritic cells carrying MUC1; RNA and DNA vaccinations; and recombinant viruses carrying the MUC1 DNA sequence. Chemotherapy of cancer aims to be toxic to the cancer cells with manageable side effects to the patient. In contrast, antigen-specific immunotherapy of cancer aims to treat the patient, such that the patient is then able to control and eventually eliminate their cancer cells. It is therefore important to know the immune status of each cancer patient prior to therapy.

引用

页码：79 / 97

页数：19

共 98 条

[1] MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines [J].

Acres, B ;

Apostolopoulos, V ;

Balloul, JM ;

Wreschner, D ;

Xing, PX ;

Ali-Hadji, D ;

Bizouarne, N ;

Kieny, MP ;

McKenzie, IFC .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) :588-594

[2] MUC1 as a target antigen for cancer immunotherapy [J].

Acres, B ;

Limacher, JM .

EXPERT REVIEW OF VACCINES, 2005, 4 (04) :493-502

[3] Do no harm [J].

不详 .

NATURE BIOTECHNOLOGY, 2013, 31 (05) :365-365

[4] MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral [J].

Apostolopoulos, V ;

Osinski, C ;

McKenzie, IFC .

NATURE MEDICINE, 1998, 4 (03) :315-320

[5]

Apostolopoulos V, 1997, J IMMUNOL, V159, P5211

[6] THE IMMUNOGENICITY OF MUC1 PEPTIDES AND FUSION PROTEIN [J].

APOSTOLOPOULOS, V ;

PIETERSZ, GA ;

XING, PX ;

LEES, CJ ;

MICHAEL, M ;

BISHOP, J ;

MCKENZIE, IFC .

CANCER LETTERS, 1995, 90 (01) :21-26

[7] Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] [J].

Apostolopoulos, Vasso ;

Pietersz, Geoffrey A. ;

Tsibanis, Anastasios ;

Tsikkinis, Annivas ;

Drakaki, Heleni ;

Loveland, Bruce E. ;

Piddlesden, Sara J. ;

Plebanski, Magdalena ;

Pouniotis, Dodie S. ;

Alexis, Michael N. ;

McKenzie, Ian F. ;

Vassilaros, Stamatis .

BREAST CANCER RESEARCH, 2006, 8 (03)

[8] Targeted therapies in non-small cell lung cancer: Proven concepts and unfulfilled promises [J].

Auberger, Jutta ;

Loeffler-Ragg, Judith ;

Wurzer, Walter ;

Hilbe, Wolfgang .

CURRENT CANCER DRUG TARGETS, 2006, 6 (04) :271-294

[9] IMMUNITY TO METHYLCHOLANTHRENE-INDUCED TUMOURS IN INBRED RATS FOLLOWING ATROPHY AND REGRESSION OF THE IMPLANTED TUMOURS [J].

BALDWIN, RW .

BRITISH JOURNAL OF CANCER, 1955, 9 (04) :652-657

[10] SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX - UNRESTRICTED RECOGNITION OF TUMOR-ASSOCIATED MUCINS BY HUMAN CYTO-TOXIC T-CELLS [J].

BARND, DL ;

LAN, MS ;

METZGAR, RS ;

FINN, OJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :7159-7163

← 1 2 3 4 5 6 7 8 9 10 →